Cancer: Epidemiology, Genomics, & Risk Assessment


Exploratory Grants in Cancer Epidemiology and Genomics Research (R21):

For research on cancer epidemiology, genomics, and risk assessment. The overarching goal is to provide support to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance cancer research, such as improving epidemiologic study data collection; validating measurement of exposures in body fluids and tissues; applying epigenetic or metabolomic approaches to cancer epidemiology research; developing and applying novel strategies for discovery of risk variants for rare cancers; understanding the population genetic architecture of cancer in understudied populations; or validating methods to extract, collect, and synthesize clinical data via electronic medical records for use in observational studies of cancer patients and survivors.

This FOA will utilize the exploratory/developmental research grant (R21) mechanism to foster cancer etiology and epidemiology research.  While these studies may involve considerable risk, they may also lead to a breakthrough in a particular area, and to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (epidemiologic, biomedical, behavioral, or clinical). 


• Pre-Application Submission: N/A
• Application Submission: 5:00 PM local time of applicant organization, Feb. 16, 2017; Jun. 16, 2017; Oct. 16, 2017; Feb. 16, 2018; Jun. 16, 2018; Oct. 16, 2018; Feb. 16, 2019


Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.